<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Activated protein C (APC) contributes to systemic <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> and anti-inflammatory activities </plain></SENT>
<SENT sid="1" pm="."><plain>APC may reduce organ damage by inhibiting thrombin generation and leukocyte activation </plain></SENT>
<SENT sid="2" pm="."><plain>Neutrophils and cerebrovascular <z:mp ids='MP_0005048'>thrombosis</z:mp> contribute to ischemic neuronal injury, suggesting that APC may be a potential <z:chebi fb="1" ids="50267">protective agent</z:chebi> for <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: We examined the effects of APC in a murine model of focal <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>After middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>/reperfusion, the average survival time in controls was 13.6 hours </plain></SENT>
<SENT sid="5" pm="."><plain>Animals that received purified human plasma-derived APC 2 mg/kg IV either 15 minutes before or 10 minutes after <z:hpo ids='HP_0001297'>stroke</z:hpo> induction survived 24 hours and were killed for neuropathological analysis </plain></SENT>
<SENT sid="6" pm="."><plain>APC 2 mg/kg given before or after <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> restored cerebral blood flow, reduced brain <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (59% to 69%; P:&lt;0.003) and <z:hpo ids='HP_0002181'>brain edema</z:hpo> (50% to 61%; P:&lt;0.05), eliminated brain infiltration with neutrophils, and reduced the number of fibrin-positive cerebral vessels by 57% (P:&lt;0.05) and 25% (nonsignificant), respectively </plain></SENT>
<SENT sid="7" pm="."><plain>The neuroprotective effect of APC was dose-dependent and associated with significant inhibition of ICAM-1 expression on ischemic cerebral blood vessels (eg, 61% inhibition with 2 mg/kg APC) </plain></SENT>
<SENT sid="8" pm="."><plain><z:mp ids='MP_0001916'>Intracerebral bleeding</z:mp> was not observed with APC </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: APC exerts anti-inflammatory, antithrombotic, and neuroprotective effects in <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>Central effects of APC are likely to be related to improved maintenance of the blood-brain barrier to neutrophils and to reduced microvascular obstructions and <z:mpath ids='MPATH_179'>fibrin deposition</z:mpath> </plain></SENT>
</text></document>